StreetAlpha.app
Home › Stocks › ETON

Eton Pharmaceuticals, Inc. (ETON)

$60.85
▼ −0.83%
LAST CLOSE · NOV 20

Eton develops and sells prescription treatments for rare diseases, mainly hormone and metabolic conditions. It last closed at $60.85 on Nov 20, down 0.83% on the day. The next earnings report for ETON is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, ETON reported EPS of $1.06 on revenue of $57.9M, with revenue up 157.9% from a year ago. Over its last 8 reports the stock moved an average of 12.6% the session after earnings. Over the last 12 months ETON insiders bought $0 of stock on the open market and sold $31.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is ETON in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ETON.

Key Stats

Last 12 months
Results
Revenue
$141.1M
+100.6% vs a year ago
Net income
$49.9M
35.3% margin
EPS (diluted)
$1.54
Free cash flow
$38.2M
27.1% margin
Valuation
Market cap
$1.8B
28.8M shares
P/E
39.5
Price over 12 month EPS
Price to sales
12.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.6M
At Sep 30
Debt
$23.1M
At Sep 30
Shareholder equity
$86.9M
Shares outstanding
28.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $21.8M$21.8MFY2021FY2022: $21.3M$21.3MFY2022FY2023: $31.6M$31.6MFY2023FY2024: $39.0M$39.0MFY2024FY2025: $80.0M$80.0MFY2025

From ETON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · After the close
Reported EPS
$1.06
Quarter ended Sep 2026
Year ago EPS
-$0.07
Same quarter last year
Revenue
$57.9M
+157.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.03Dec '24Mar 2025: -$0.06Mar '25Jun 2025: -$0.10Jun '25Sep 2025: -$0.07Sep '25Dec 2025: $0.06Dec '25Mar 2026: $0.05Mar '26Jun 2026: $0.35Jun '26Sep 2026: $1.06Sep '26Latest $1.06
Revenue by quarter
Dec 2024: $11.6MDec '24Mar 2025: $17.3MMar '25Jun 2025: $18.9MJun '25Sep 2025: $22.5MSep '25Dec 2025: $21.3MDec '25Mar 2026: $24.3MMar '26Jun 2026: $37.6MJun '26Sep 2026: $57.9MSep '26Latest $57.9M
How ETON moved after its last 8 reports
Average move the session after a report ±12.6%
Nov 5, 2026After the close+19.8%
Aug 13, 2026After the close+44.3%
May 14, 2026After the close+1.0%
Mar 19, 2026After the close+7.5%
Nov 6, 2025After the close−11.7%
Aug 7, 2025After the close+12.3%
May 13, 2025After the close+0.3%
Mar 18, 2025Time not announced−4.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ETONStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ETON
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ETON

Technical Analysis

ETON · as of the Nov 20 close · updated each morning
Uptrend

The stock is 5% above its 20 day and 9% above its 50 day average. It is 36% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 55). The nearest support is the Pivot at $60.56, and the nearest resistance the Pivot R1 at $61.94.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 6.2%/day
Key levels
$70.6452 week high+16.1%
$62.91Swing high (Sep 2)+3.4%
$61.94Pivot R1+1.8%
$60.85Last close
$60.56Pivot−0.5%
$59.47Pivot S1−2.3%
$58.24Swing low (Aug 31)−4.3%
$57.6220 day average−5.3%
$55.6750 day average−8.5%
$52.58100 day average−13.6%
$39.04200 day average−35.8%
$14.2752 week low−76.5%
Indicators
RSI (14)55.46Middle of its rangeNeutral
MACD2.56Above its signal lineBullish
Stochastic60.9Middle of its rangeNeutral
ADX (14)23.7Weak trend
Williams %R-41.5Oversold below −80, overbought above −20Neutral
CCI (20)32.1Oversold below −100, overbought above 100Neutral
Rate of change+7.8%Change over 10 sessionsBullish
ATR (14)$3.77Typical daily range, 6.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ETON

What happened before

See how ETON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ETON usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ETON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ETONHow many large options trades hit ETON, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ETON Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲144 buying vs 79 selling
  • ▲Held by funds +3.5 pts
  • ▲Funds holding +49
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding214165+29.7%
In funds' top 1065+20.0%
Held by funds76.8%73.3%+3.5 pts
New / increased72 / 7255 / 57+28.6%
Reduced / sold out52 / 2735 / 5+97.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ETON institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ETON Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$31.0M11 sales · 7 insiders
2026-05 sold $7.1M2026-06 sold $1.6M2026-07 sold $5.8M2026-08 sold $10.7M2026-10 sold $229K2026-11 sold $5.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 10Ipek Erdogan-TrinkausChief Commercial OfficerSale3,500$67.41$236K
Nov 10Charles J CasamentoDirectorSale80,555$66.35$5.3M
Oct 6David KrempaChief Business OfficerSale4,166$55.07$229K
Aug 28Paul V MaierDirectorSale50,000$59.07$3.0M
Aug 24David KrempaChief Business OfficerSale25,000$65.07$1.6M
Aug 20Sean BrynjelsenPresident & CEOSale100,000$60.88$6.1M
Every insider buy and sale for ETON over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ETON insider trades →

From SEC Form 4 filings by ETON's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ETON is in one of them and how their past ETON trades turned out.

ETON in the AI portfolios
Loading…

ETON News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ETON in an article yet. Here's the latest on the wider market.

ETON in the news

About Eton Pharmaceuticals

Eton develops and sells prescription treatments for rare diseases. Its products include hormone replacement therapies for adrenal insufficiency, a treatment for a childhood growth disorder, and products for metabolic conditions such as phenylketonuria, Wilson disease and tyrosinemia. The company is based in Deer Park, Illinois, and sells its products in the United States through its own sales force. Its products reach patients through specialty pharmacies, and its customers are mainly doctors who treat patients with these conditions.

Headquarters
Deer Park, IL